期刊
JOURNAL OF CLINICAL PHARMACOLOGY
卷 46, 期 2, 页码 140-148出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/0091270005283461
关键词
high-affinity melatonin MT1/MT2 receptor; insomnia; pharmacokinetics; single rising doses; tolerance
Ramelteon is a selective MT1/MT2 receptor agonist, indicated for insomnia treatment. Safety, tolerance, pharmacokinetics, and cognitive performance were evaluated following increasing ramelteon doses. Healthy adults (35-65 years) were randomly assigned to receive 1 of 5 oral ramelteon doses (4,8,16, 32, or 64 mg; n 8 per group) or placebo (n = 20). C-max and AUC(infinity) (mean [%CVI) increased with each dose: C-max = 1.15 (109), 5.73 (97), 6.92 (77),17.4 (76), and 25.9 (77) ng/mL, respectively, and AUC(infinity) = 1.71 (114), 6.95 (108), 9.88 (78), 22.5 (80), and 36.1 (71 ng.h/mL), respectively. Mean T-max values of 0.75 to 0.94 hours and mean elimination half-life of 0.83 to 1.90 hours remained relatively constant. Ramelteon was extensively metabolized. Besides ramelteon, 4 metabolites, M-I, M-II, M-III, and M-IV were measured in serum. Metabolite M-II, which has shown weak ramelteon-like activity in vitro, was the major metabolite in serum. Digit Symbol Substitution Test and visual analog scale alertness scores were similar across all dose groups and did not differ from placebo. All adverse events were mild or moderate and resolved before study completion.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据